BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
On December 5, 2016, Bio-Path Holdings, Inc. (the Company) issued
a press release titled, Bio-Path Holdings Presents Clinical Data
Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia
at the 58th Annual American Society of Hematology Annual Meeting.
A copy of such press release is attached hereto as Exhibit 99.1.
Item 9.01Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number | Description |
| 99.1 | Press Release dated December 5, 2016 |
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Recent Trading Information
BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) closed its last trading session down -0.03 at 1.28 with 85,277 shares trading hands.
